[1]郑继荣.枯草杆菌二联活菌肠溶胶囊联合改良序贯疗法治疗胃肠炎的疗效与安全性[J].医学信息,2023,36(23):111-114.[doi:10.3969/j.issn.1006-1959.2023.23.028]
　ZHENG Ji-rong.Efficacy and Safety of Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules Combined with Modified Sequential Therapy in the Treatment of Gastroenteritis[J].Journal of Medical Information,2023,36(23):111-114.[doi:10.3969/j.issn.1006-1959.2023.23.028]
点击复制

枯草杆菌二联活菌肠溶胶囊联合改良序贯疗法治疗胃肠炎的疗效与安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年23期
页码:
111-114
栏目:
药物与临床
出版日期:
2023-12-01

文章信息/Info

Title:
Efficacy and Safety of Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules Combined with Modified Sequential Therapy in the Treatment of Gastroenteritis
文章编号:
1006-1959（2023）23-0111-04
作者:
郑继荣
（玉山县黄家驷医院/玉山县人民医院内科，江西 玉山 334700）
Author(s):
ZHENG Ji-rong
(Outpatient Department of Internal Medicine,Yushan County Huangjiasi Hospital/Yushan County People’s Hospital,Yushan 334700,Jiangxi,China)
关键词:
枯草杆菌二联活菌肠溶胶囊; 改良序贯疗法; 胃肠炎; 药物安全性
Keywords:
Live combined bacillus subtilis and enterococcus faecium enteric-coated capsules; Modified sequential therapy; Gastroenteritis; Drug safety
分类号:
R574
DOI:
10.3969/j.issn.1006-1959.2023.23.028
文献标志码:
A
摘要:
目的 评估枯草杆菌二联活菌肠溶胶囊联合改良序贯疗法治疗胃肠炎的疗效与安全性。方法 选取2020年2月-2023年2月在我院诊治的64例胃肠炎患者为研究对象，采用随机数字表法分为对照组和观察组，各32例。对照组采用改良序贯疗法治疗，观察组在对照组基础上给予枯草杆菌二联活菌肠溶胶囊治疗。比较两组临床疗效、临床症状（腹泻、腹痛、呕吐）改善时间、肠道菌群（双歧杆菌、乳杆菌、大肠埃希菌）水平、炎症因子[白介素-6（IL-6）、C-反应蛋白（CRP）]水平以及不良反应发生情况。结果 观察组治疗总有效率为93.75%，高于对照组的81.25%（P＜0.05）；观察组腹泻、腹痛、呕吐改善时间均短于对照组（P＜0.05）；两组治疗后双歧杆菌、乳杆菌、大肠埃希菌计数均高于治疗前，且观察组高于对照组（P＜0.05）；两组治疗后IL-6、CRP水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为6.25%，低于对照组的9.38%，差异无统计学意义（P＞0.05）。结论 枯草杆菌二联活菌肠溶胶囊联合改良序贯疗法治疗胃肠炎可提高总有效率，缩短临床症状改善时间，提升胃肠道有益菌水平，降低炎症因子水平，且不会增加不良反应，值得临床应用。
Abstract:
Objective To evaluate the efficacy and safety of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with modified sequential therapy in the treatment of gastroenteritis.Methods A total of 64 patients with gastroenteritis diagnosed and treated in our hospital from February 2020 to February 2023 were selected as the research objects. They were divided into control group and observation group by random number table method, with 32 cases in each group. The control group was treated with modified sequential therapy, and the observation group was treated with Bacillus subtilis enteric-coated capsules on the basis of the control group. The clinical efficacy, improvement time of clinical symptoms (diarrhea, abdominal pain, vomiting), levels of intestinal flora (bifidobacterium, lactobacillus, escherichia coli), levels of inflammatory factors [interleukin-6 (IL-6), C-reactive protein (CRP)] and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.75%, which was higher than 81.25% in the control group (P＜0.05). The improvement time of diarrhea, abdominal pain and vomiting in the observation group was shorter than that in the control group (P＜0.05). After treatment, the counts of Bifidobacterium, Lactobacillus and Escherichia coli in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P＜0.05). After treatment, the levels of IL-6 and CRP in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P＜0.05). The incidence of adverse reactions in the observation group was 6.25%, which was lower than 9.38% in the control group, but the difference was not statistically significant (P>0.05).Conclusion Live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with modified sequential therapy can improve the total effective rate of gastroenteritis, shorten the improvement time of clinical symptoms, improve the level of beneficial bacteria in the gastrointestinal tract, reduce the level of inflammatory factors, and will not increase adverse reactions, which is worthy of clinical application.

参考文献/References:

[1]卢燕,杜静,赵景润,等.雌激素对溃疡性结肠炎患者NF-κB、IL-6及NO表达的影响[J].国际免疫学杂志,2019,42(1):38-48.[2]杨连雷,陈梦娜,李善高,等.NOD样受体蛋白3炎症小体表达水平与溃疡性结肠炎病变活动的关系[J].中华消化杂志,2019,39(4):229-236.[3]赵建杰,朱叶珊.维生素D治疗慢性非特异性溃疡性结肠炎的疗效评价[J].山西医药杂志,2018,45(12):1424-1425.[4]付伟,韦艳丹.蒙脱石散联合布拉氏酵母菌对小儿急性胃肠炎患儿炎症反应及症状改善的影响[J].山西医药杂志,2020,49(9):1141-1142.[5]朱凯,叶小雪,黄适.中医辨证施治联合西医常规治疗急性肠胃炎的疗效及对炎症因子水平的影响[J].辽宁中医杂志,2019,46(4):785-787.[6]白晓莉.间苯三酚联合依替米星对急性胃肠炎痉挛性腹痛患者疼痛症状及炎症因子水平的影响分析[J].实用医院临床杂志,2017,14(6):176-178.[7]刘晓,邹龙.酪酸杆菌双歧杆菌二联活菌联合蒙脱石散对急性胃肠炎患者血清降钙素原、白细胞介素6和白细胞介素8的影响[J].医学综述,2017,20(8):105-107.[8]Farahmand M,Jalilvand S,Arashkia A,et al.Association between circulating rotavirus genotypes and histo-blood group antigens in the children hospitalized with acute gastroenteritis in Iran[J].Journal of Medical Virology,2021,93(8):4817-4823.[9]王绪国,侯莉.蒙脱石散联合布拉酵母菌治疗小儿急性胃肠炎的效果及对血清炎症因子的影响[J].湖南师范大学学报,2019,16(5):113-116.[10]高志兴,杨玉,徐贵所.头孢他啶与酪酸梭菌活菌胶囊对急性阑尾炎患者微创术后的胃肠功能的恢复及其对炎症因子水平的影响[J].抗感染药学,2019,16(2):122-124.[11]王新辉,张健,刘坤.酪酸杆菌双歧杆菌二联活菌联合马来酸曲美布汀治疗急性胃肠炎疗效观察[J].齐齐哈尔医学院学报,2017,15(1):29-31.[12]杨辉,李小芹,于静,等.金双歧联合吗丁啉治疗小儿胃肠炎对患儿免疫功能、氧化应激水平影响分析[J].实验与检验医学,2021,39(1):177-180.[13]姜云达,岳德永,顾立华,等.头孢克肟治疗急性细菌性肠炎患者临床效果及对血清炎症因子的影响研究[J].国际检验医学杂志,2017,38(23):3225-3227.[14]曹鑫.奥美拉唑钠注射液联合地衣芽孢杆菌活菌胶囊对急性胃肠炎患者症状改善及炎性水平的影响[J].基层医学论坛,2021,25(4):511-512.[15]王横溢.益生菌辅助治疗小儿轮状病毒性胃肠炎的疗效和安全性分析[J].实用中西医结合临床,2020,10(8):109-110.[16]黄淑顺,李敏.藿香正气丸联合磷酸铝凝胶治疗急性胃肠炎的临床研究[J].现代药物与临床,2017,32(8):1470-1473.[17]Kim YJ,Park KH,Park DA,et al.Guideline for the Antibiotic use in Acute Gastroenteritis[J].Infect Chemother,2019,51(2):217-243.[18]李洁,杨扬,梁志超,等.北京地区五岁以下儿童病毒性急性胃肠炎病原构成与临床特征分析[J].中华预防医学杂志,2020,54(10):1104-1110.[19]李剑,陈俊平,陈倩莹,等.双歧杆菌三联活菌联合奥美拉唑治疗急性肠胃炎[J].实用中西医结合临床,2019,19(9):128-129.[20]胡维,贺琼.酪酸梭菌二联活菌联合蒙脱石散对急性胃肠炎患者的临床疗效[J].宁夏医科大学学报,2017,30(8):143-145.

相似文献/References:

[1]汪尚勇,姜立飞.双歧杆菌乳杆菌三联活菌联合改良序贯疗法治疗Hp阳性慢性萎缩性胃炎的疗效与安全性[J].医学信息,2023,36(24):69.[doi:10.3969/j.issn.1006-1959.2023.24.013]
　WANG Shang-yong,JIANG Li-fei.Efficacy and Safety of Live Combined Bifidobacterium and Lactobacillus Combined with Modified Sequential Therapy in the Treatment of Hp Positive Chronic Atrophic Gastritis[J].Journal of Medical Information,2023,36(23):69.[doi:10.3969/j.issn.1006-1959.2023.24.013]

更新日期/Last Update: 1900-01-01